Hana Securities forecasted on the 20th that Samil Pharmaceutical's performance will significantly improve starting this year.
Choi Jae-ho, a researcher at Hana Securities, explained, "New products such as the age-related macular degeneration treatment eye drops ‘Amelibu’ and the dry eye treatment eye drops ‘Rebakei’, which were launched last year, will drive performance improvement." He added, "The glaucoma treatment eye drops ‘Monoprost’ recorded sales of approximately 10 billion KRW last year, marking a 19.4% increase compared to the previous year."
He analyzed, "This year, they will sell Samsung Bioepis's Eylea biosimilar ‘Afilibu’," adding, "As of last year, Eylea's domestic sales amounted to about 80 billion KRW, and considering the development status of competitors, it is expected to contribute at least 10 billion KRW annually in sales."
Researcher Choi stated, "Samil Pharmaceutical holds a pipeline of multiple new drugs as part of its additional growth drivers," and "attention should be paid to the value of ‘Roarsibivint’, for which they hold exclusive domestic distribution rights."
He continued, "Roarsibivint is an innovative new drug introduced from the US-based Biophlice company," and "as of 2022, it is an osteoarthritis treatment targeting stage 2 to 3 patients, who account for about 65% of approximately 4.18 million patients in Korea." He emphasized, "There is no global new drug for fundamental osteoarthritis treatment," and "Roarsibivint secured efficacy data on knee joint space width (JSW) improvement through a Phase 3 clinical trial in the US in the fourth quarter of last year."
Researcher Choi expressed expectations, "After applying to the US FDA in the second half of this year, Samil Pharmaceutical plans to apply to the Korean Ministry of Food and Drug Safety in the first half of next year," adding, "The FDA application alone will act as a catalyst for stock price increase."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
